Abstract
A patient with homocystinuria, a risk factor of arterial and venous thrombosis, developed cerebral venous thrombophlebitis before the age of twenty years. As she was B6 sensible, she was given 250 mg/d of pyridoxine and homocysteinemia was well controlled. Unfortunately, at the age of 40, she developed progressive weakness, with a major increase of plasma CPK values (4110 UI/l, normal < 160). Severe rhabdomyolysis was observed, and muscle biopsy showed necrotic fibres. She died of pulmonary embolism. B6 vitamin is not known to be toxic. However, excessive intake can cause ataxia and severe neuropathy. But some authors have reported that a short term administration of 500 mg/d of pyridoxine to a one-month old child caused a rhabdomyolysis, and this observation might evocate a particular susceptibility of our homocystinuric patient to B6 vitamin therapy.
Keywords: Homocystinuria, homocysteine, cystathionine b-synthase, thromboembolic accident, Vitamin B6, rhabdomyolysis
Letters in Drug Design & Discovery
Title: Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?
Volume: 3 Issue: 2
Author(s): M. Candito, P. Dellamonica, P. Hofman and Emmanuel V. Obberghen
Affiliation:
Keywords: Homocystinuria, homocysteine, cystathionine b-synthase, thromboembolic accident, Vitamin B6, rhabdomyolysis
Abstract: A patient with homocystinuria, a risk factor of arterial and venous thrombosis, developed cerebral venous thrombophlebitis before the age of twenty years. As she was B6 sensible, she was given 250 mg/d of pyridoxine and homocysteinemia was well controlled. Unfortunately, at the age of 40, she developed progressive weakness, with a major increase of plasma CPK values (4110 UI/l, normal < 160). Severe rhabdomyolysis was observed, and muscle biopsy showed necrotic fibres. She died of pulmonary embolism. B6 vitamin is not known to be toxic. However, excessive intake can cause ataxia and severe neuropathy. But some authors have reported that a short term administration of 500 mg/d of pyridoxine to a one-month old child caused a rhabdomyolysis, and this observation might evocate a particular susceptibility of our homocystinuric patient to B6 vitamin therapy.
Export Options
About this article
Cite this article as:
Candito M., Dellamonica P., Hofman P. and Obberghen V. Emmanuel, Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?, Letters in Drug Design & Discovery 2006; 3 (2) . https://dx.doi.org/10.2174/157018006775789720
DOI https://dx.doi.org/10.2174/157018006775789720 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Cardiovascular & Hematological Agents in Medicinal Chemistry Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design The Successful Treatment of Pulmonary Embolism as a Complication after Uterine Fibroid Embolization (Case Report)
Current Women`s Health Reviews Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues
Current Vascular Pharmacology Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Mesenchymal Stem Cells as a Treatment Strategy for Coronavirus Disease 2019 (COVID-19): Need for Authority Regulations and Clinical Guidelines
Current Stem Cell Research & Therapy Concise Review of the Rationale for Pulmonary Embolism Treatment and Endovascular Device Therapies
Current Cardiology Reviews Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
Current Drug Metabolism PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Prophylactic Neuroprotection
Current Drug Targets Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Cyano Acrylate Polymers in Medical Applications
Recent Patents on Materials Science